Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

hsa_circWDR37_016 Regulates Hypoxia-Induced Proliferation of Pulmonary Arterial Smooth Muscle Cells.

Tytuł:
hsa_circWDR37_016 Regulates Hypoxia-Induced Proliferation of Pulmonary Arterial Smooth Muscle Cells.
Autorzy:
Li SS; School of Medicine, Nankai University, Tianjin, China.
Liang S; School of Medicine, Nankai University, Tianjin, China.; Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, China.; Tianjin Key Laboratory of Human Development and Reproductive Regulation, Tianjin, China.
Long Y; School of Medicine, Nankai University, Tianjin, China.
Chen X; School of Medicine, Nankai University, Tianjin, China.; Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, China.; Tianjin Key Laboratory of Human Development and Reproductive Regulation, Tianjin, China.
Jin X; School of Medicine, Nankai University, Tianjin, China.; Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, China.; Tianjin Key Laboratory of Human Development and Reproductive Regulation, Tianjin, China.
Źródło:
Cardiovascular therapeutics [Cardiovasc Ther] 2022 Jan 17; Vol. 2022, pp. 7292034. Date of Electronic Publication: 2022 Jan 17 (Print Publication: 2022).
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: 2019- : [London, United Kingdom] : Hindawi
Original Publication: Oxford : Wiley-Blackwell, c2008-c2018.
MeSH Terms:
Cell Hypoxia*
Myocytes, Smooth Muscle/*cytology
RNA, Circular/*genetics
Cell Movement ; Cell Proliferation ; Cells, Cultured ; Humans ; MicroRNAs/genetics ; Pulmonary Artery/cytology
References:
Hypertension. 2012 May;59(5):1006-13. (PMID: 22392900)
Mol Ther Nucleic Acids. 2020 Sep 23;22:530-541. (PMID: 33230455)
Mol Cell. 2007 Jul 6;27(1):91-105. (PMID: 17612493)
Nat Rev Cardiol. 2020 Feb;17(2):85-95. (PMID: 31406341)
Hypertension. 2020 Mar;75(3):668-679. (PMID: 32008463)
Aging Dis. 2020 Jul 23;11(4):1009-1020. (PMID: 32765960)
Mol Med Rep. 2019 Feb;19(2):783-791. (PMID: 30535469)
World J Gastroenterol. 2015 Nov 7;21(41):11680-7. (PMID: 26556995)
Am J Cancer Res. 2019 Jun 01;9(6):1118-1126. (PMID: 31285946)
Tumour Biol. 2017 Apr;39(4):1010428317697575. (PMID: 28378633)
Mol Ther Nucleic Acids. 2020 Sep 28;23:1007-1019. (PMID: 33614247)
Exp Cell Res. 2020 May 1;390(1):111939. (PMID: 32142853)
Cardiovasc Res. 2020 Oct 1;116(12):1937-1947. (PMID: 32109276)
Phytomedicine. 2019 Nov;64:152925. (PMID: 31465982)
J Am Soc Hypertens. 2015 Mar;9(3):221-34. (PMID: 25660363)
EMBO J. 2019 Aug 15;38(16):e100836. (PMID: 31343080)
Respir Res. 2020 Jul 16;21(1):186. (PMID: 32678044)
Genome Res. 2009 Jan;19(1):92-105. (PMID: 18955434)
Am J Cancer Res. 2017 Jul 01;7(7):1566-1576. (PMID: 28744405)
Eur Respir Rev. 2017 Dec 20;26(146):. (PMID: 29263173)
Am J Physiol Lung Cell Mol Physiol. 2019 Mar 1;316(3):L547-L557. (PMID: 30628484)
Front Cardiovasc Med. 2021 Jul 07;8:682357. (PMID: 34307497)
Adv Exp Med Biol. 2017;978:23-37. (PMID: 28523539)
Eur Respir J. 2019 Jan 24;53(1):. (PMID: 30545968)
Am J Respir Crit Care Med. 2017 Feb 15;195(4):515-529. (PMID: 27648837)
Braz J Med Biol Res. 2018 Oct 18;51(12):e7437. (PMID: 30365723)
Pulm Circ. 2018 Jul-Sep;8(3):2045894018794051. (PMID: 30036135)
Int J Mol Med. 2018 Sep;42(3):1353-1366. (PMID: 29956720)
Nat Protoc. 2008;3(6):1101-8. (PMID: 18546601)
N Engl J Med. 2014 Jan 30;370(5):455-65. (PMID: 24476434)
Compr Physiol. 2020 Mar 12;10(2):713-765. (PMID: 32163206)
Nat Struct Mol Biol. 2011 Sep 11;18(10):1139-46. (PMID: 21909094)
Cell. 2011 Aug 5;146(3):353-8. (PMID: 21802130)
Sci Rep. 2016 Aug 03;6:30919. (PMID: 27484176)
Eur Rev Med Pharmacol Sci. 2018 Jul;22(14):4642-4647. (PMID: 30058705)
Sci Rep. 2015 Jan 27;5:8057. (PMID: 25624062)
Nat Rev Mol Cell Biol. 2020 Aug;21(8):475-490. (PMID: 32366901)
Nat Rev Genet. 2019 Nov;20(11):675-691. (PMID: 31395983)
Mol Cell Biochem. 2021 Jan;476(1):109-123. (PMID: 32975695)
Am J Physiol Lung Cell Mol Physiol. 2018 Apr 1;314(4):L606-L616. (PMID: 29074487)
Biomed Pharmacother. 2018 Oct;106:1108-1115. (PMID: 30119177)
Genes (Basel). 2016 Dec 05;7(12):. (PMID: 27929395)
Mol Ther Nucleic Acids. 2019 Jun 7;16:118-129. (PMID: 30861414)
Epigenomics. 2016 May;8(5):619-32. (PMID: 27097056)
Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2677-86. (PMID: 25941359)
Adv Exp Med Biol. 2016;903:29-53. (PMID: 27343087)
Life Sci. 2020 Aug 15;255:117837. (PMID: 32450175)
BMJ. 2018 Mar 14;360:j5492. (PMID: 29540357)
Genome Biol. 2003;5(1):R1. (PMID: 14709173)
Am J Respir Cell Mol Biol. 2018 Feb;58(2):181-193. (PMID: 28915060)
Substance Nomenclature:
0 (MIRN138 microRNA, human)
0 (MicroRNAs)
0 (RNA, Circular)
Entry Date(s):
Date Created: 20220204 Date Completed: 20220207 Latest Revision: 20220531
Update Code:
20240104
PubMed Central ID:
PMC8786516
DOI:
10.1155/2022/7292034
PMID:
35116078
Czasopismo naukowe
Pulmonary arterial hypertension (PAH) is characterized by abnormal remodeling of pulmonary vessel walls caused by excessive pulmonary arterial smooth muscle cell (PASMC) proliferation. Our previous clinical studies have demonstrated the importance of the downregulated circRNA in PAH. However, the role of upregulated circRNAs is still elusive. Here, we identified the upregulated circRNA in PAH patients, hsa_circWDR37_016 (circWDR37), as a key regulator of hypoxic proliferative disorder of pulmonary arterial smooth muscle cells (PASMCs). Quantitative real-time PCR (qRT-PCR) analysis validated that exposure to hypoxia markedly increased the circWDR37 level in cultured human PASMCs. As evidenced by flow cytometry, 5-ethynyl-2'-deoxyuridine (EdU) incorporation, wound healing, and Tunel assay, silencing of endogenous circWDR37 attenuated proliferation and cell-cycle progression in hypoxia-exposed human PASMCs in vitro. Furthermore, bioinformatics and Luciferase assay showed that circWDR37 directly sponged hsa-miR-138-5p (miR-138) and was involved in the immunoregulatory and inflammatory processes of PAH. Together, these studies suggested new insights into circRNA regulated the pathology of PAH, providing a new potential therapeutic target for PAH treatment.
Competing Interests: All authors declare that they have no conflict of interest.
(Copyright © 2022 Shan-Shan Li et al.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies